Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Insider Arturo Md Molina Sells 30,514 Shares of Stock

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) insider Arturo Md Molina sold 30,514 shares of the firm’s stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $55.74, for a total transaction of $1,700,850.36. Following the transaction, the insider now directly owns 83,892 shares of the company’s stock, valued at approximately $4,676,140.08. This represents a 26.67 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Protagonist Therapeutics Stock Down 0.2 %

Protagonist Therapeutics stock opened at $54.78 on Friday. The firm has a 50-day moving average price of $39.63 and a two-hundred day moving average price of $42.24. The firm has a market capitalization of $3.36 billion, a price-to-earnings ratio of 20.59 and a beta of 2.34. Protagonist Therapeutics, Inc. has a 52-week low of $24.22 and a 52-week high of $60.60.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its earnings results on Friday, February 21st. The company reported $1.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.09) by $2.07. Protagonist Therapeutics had a net margin of 52.76% and a return on equity of 34.68%. The firm had revenue of $170.64 million during the quarter, compared to analyst estimates of $56.65 million. Research analysts expect that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current year.

Institutional Trading of Protagonist Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in PTGX. FNY Investment Advisers LLC bought a new stake in shares of Protagonist Therapeutics during the 4th quarter worth about $38,000. GF Fund Management CO. LTD. bought a new stake in shares of Protagonist Therapeutics during the 4th quarter worth about $48,000. Covestor Ltd raised its position in shares of Protagonist Therapeutics by 5,200.0% during the 4th quarter. Covestor Ltd now owns 1,643 shares of the company’s stock worth $63,000 after buying an additional 1,612 shares in the last quarter. Harvest Fund Management Co. Ltd bought a new stake in shares of Protagonist Therapeutics during the 3rd quarter worth about $69,000. Finally, KBC Group NV raised its position in shares of Protagonist Therapeutics by 54.4% during the 4th quarter. KBC Group NV now owns 2,093 shares of the company’s stock worth $81,000 after buying an additional 737 shares in the last quarter. 98.63% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. StockNews.com lowered shares of Protagonist Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, December 10th. Wedbush reaffirmed an “outperform” rating on shares of Protagonist Therapeutics in a report on Tuesday. JPMorgan Chase & Co. lifted their price target on shares of Protagonist Therapeutics from $53.00 to $57.00 and gave the company an “overweight” rating in a report on Tuesday, March 4th. JMP Securities reaffirmed a “market outperform” rating and issued a $58.00 price target on shares of Protagonist Therapeutics in a report on Friday, February 7th. Finally, BMO Capital Markets lifted their price target on shares of Protagonist Therapeutics from $62.00 to $72.00 and gave the company an “outperform” rating in a report on Tuesday. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $61.22.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.